Company Profile

Our History is Operational Excellence

Our Future is Opportunity in Action

SGN NanoPharma Inc became operational in August 2010 with the acquisition of the MNP Technology Platform in its entirety from Novavax Inc. (Nasdaq: NVAX).

Novavax spent several years and ~$100 million in developing the 1st generation MNP Platform and obtained FDA approval for Estrasorb (estrogen topical lotion for relief of menopausal symptoms) and successfully completed a Phase I trial with a Testosterone MNP formulation.

After acquiring the MNP Technology from Novavax, SGN Nanopharma has refined it to improve the long-term stability of the technology.

  • We have successfully formulated over 20 already marketed drugs with varying solubility and physical characteristics to establish the versatility of the MNP Platform.
  • We now have over 2 years of stability data for 20+ formulations establishing the translatability of this platform into successful commercial products.
  • We successfully scaled up and launched in India a MNP Nanocyclosporine formulation for dry eye disease and are in the middle of one Phase II and in the process of initiating two Phase II, proof of concept, clinical studies in India.
  • Since our technology is ideally suited to formulate and deliver poorly water soluble compounds like Cannabinoids, we made the strategic decision to focus on developing several MNP NanoCannabinoid formulations and expect to file NanoCannabinoid Phase I INDs in 1H2020.
  • We currently have one patent issued in the US and India and an additional pending with the USPTO and anticipate additional filings this year.

Developing Next Generation NanoCannabinoid Formulations

SGN NanoPharma is an innovative, clinical-stage and revenue-generating developer of nanotherapeutics. The Company combines proprietary nanotechnologies with structural biology to generate superior solutions by (a) reformulating FDA approved drugs that are sub-optimal and (b) by developing novel therapies. SGN is committed to the development of nano-cannabinoid candidate products targeting topical delivery, increased bioavailability, and reduced psychotropic effects. Our aim is to safely deliver large dose therapies as an alternative to many traditional medicines such as opiates, which are currently considered over prescribed and potentially life-threatening.

SGN Nanopharma Inc.
3720 Spectrum Blvd.
Suites 125 B&C
Tampa, FL 33612

General Inquiries

Tel: +1 (813) 615-2400

Incorporation: February 25, 2010

Fiscal Year End: December, 31

Get News Updates